VERAPAMIL REVERSES ABNORMAL [CA2+]I AND CARBOHYDRATE-METABOLISM OF PMNL OF DIALYSIS PATIENTS

被引：39

作者：

HORL, WH

HAAGWEBER, M

MAI, B

MASSRY, SG

机构：

[1] UNIV SO CALIF,SCH MED,DEPT MED,DIV NEPHROL,LOS ANGELES,CA 90033

[2] UNIV VIENNA,DEPT MED,DIV NEPHROL,VIENNA,AUSTRIA

来源：

KIDNEY INTERNATIONAL | 1995年 / 47卷 / 06期

关键词：

D O I：

10.1038/ki.1995.240

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The basal levels of cytosolic calcium ([Ca2+]i) of polymorphonuclear leukocytes (PMNL) are elevated in hemodialysis ((HD) patients, and this abnormality has been implicated in the dysfunction of the PMNL of these patients. The elevated [Ca2+]i appears to be due to PTH-induced entry of calcium into PMNL, an action that may be prevented by calcium channel-blockers. We examined [Ca2+]i and carbohydrate metabolism of PMNL of normal subjects and of HD patients before, after eight to nine weeks of verapamil therapy (120 mg/day), and after eight to ten weeks of discontinuation of verapamil treatment. In HD patients, the basal levels of [Ca2+]i of PMNL are elevated and their glucose uptake, the activity of total and active forms of glycogen synthetase, and glycogen content are reduced compared to values in normal subjects (P < 0.01). These derangements were normalized after verapamil therapy and re-emerged after discontinuation of treatment with verapamil despite no change in blood; levels of PTH. The results indicate that the elevation in [Ca2+]i of PMNL and the consequent derangements in carbohydrate metabolism of these cells are treatable with a calcium channel blocker. The data assign a valuable role for calcium channel blockers for the amelioration of some aspects of cell dysfunction of uremia.

引用

页码：1741 / 1745

页数：5

共 40 条

[1] Massry S.G., Fadda G.Z., Chronic renal failure is a state of cellular calcium toxicity, Am J Kidney Dis, 21, pp. 81-86, (1993)
[2] Fadda G.Z., Hajjar S.M., Perna A.F., Zhou X.-J., Lipson L.G., Massry S.G., On the mechanism of impaired insulin secretion in chronic renal failure, J Clin Invest, 87, pp. 255-261, (1992)
[3] Smogorzewski M., Koureta P., Fadda G.Z., Perna F., Massry S.G., Chronic excess of parathyroid hormone in vivo increases resting levels of cytosolic calcium in brain synaptosomes: Studies in the presence and absence of chronic renal failure, JASN, 1, pp. 1162-1168, (1991)
[4] Kiersztejn M., Smogorzewski M., Thanakitcharu P., Fadda G.Z., Massry S.G., Decreased O<sub>2</sub> consumption by PMNL from humans and rats with CRF: Role of secondary hyperparathyroidism, Kidney Int, 42, pp. 602-609, (1992)
[5] Stojeceva-Taneva O., Smogorzewski M., Fadda G.Z., Massry S.G., Elevated basal levels of cytosolic calcium of thymocytes in chronic renal failure, Am J Nephrol, 13, pp. 155-159, (1993)
[6] Alexiewicz J.M., Smogerzweski M., Fadda G.Z., Massry S.G., Impaired phagocytosis in dialysis patients: Studies on mechanisms, Am J Nephrol, 11, pp. 102-111, (1991)
[7] Gaciong Z., Alexiewicz J.M., Linker-Israeli M., Shulman I.A., Pitts T.O., Massry S.G., Inhibition of immunoglobulin production by parathyroid hormone: Implications in chronic renal failure, Kidney Int, 40, pp. 96-106, (1991)
[8] Raine A.E.G., Bedford L., Simpson A.W.M., Ashley C.H.C., Brown R., Woodhead J.S., Ledingham J.G.G., Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure, Kidney Int, 43, pp. 700-705, (1993)
[9] Fadda G.Z., Thanakitcharu P., Smogorzewski M., Massry S.G., Parathyroid hormone raises cytosolic calcium in pancreatic islets: Study on mechanisms, Kidney Int, 43, pp. 554-560, (1993)
[10] Stojeceva-Taneva O., Fadda G.Z., Smogorzewski M., Massry S.G., Parathyroid hormone increases cytosolic calcium of thymocytes, Nephron, 64, pp. 592-599, (1993)

← 1 2 3 4 →